Showing 4991-5000 of 7243 results for "".
- Alopecia Areata Linked to Increased Psychiatric, Autoimmune Conditionshttps://practicaldermatology.com/news/alopecia-areata-linked-increased-psychiatric-autoimmune-conditions/2467632/A new retrospective analysis indicated that patients with newly diagnosed alopecia areata (AA) tended to have higher prevalence of psychiatric and autoimmune comorbidities. Researchers for the study focused on adolescents and adults aged 12-64 years diagnosed with AA (compared to a control
- Committee Recommends Expanded Indications for Spesolimab, Targeting Generalized Pustular Psoriasishttps://practicaldermatology.com/news/spevigo-gets-expanded-indication-generalized-pustular-psoriasis-treatment-and-prevention/2467564/The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval expanded indications for spesolimab (SPEVIGO®), according to a press release. A humanized selective IgG1 antibody targeting the interleu
- FDA Approves Deuruxolitinib for Alopecia Areatahttps://practicaldermatology.com/news/fda-approves-deuruxolitinib-alopecia-areata/2467563/The U.S. Food and Drug Administration (FDA) has approved deuruxolitinib 8-mg tablets for the treatment of adults with severe alopecia areata, Sun Pharmaceuticals Industries Limited announced in a press release. Deuroxolitinib is available from Sun Pharma under the name LEQSELVI. "
- DART Releases New Clinical Guidelines for Nonmelanoma Skin Cancer Treatmenthttps://practicaldermatology.com/news/dart-releases-new-clinical-guidelines-nonmelanoma-skin-cancer-treatment/2467534/The Dermatology Association of Radiation Therapy (DART) has published new clinical guidelines for the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) using image-guided superficial radiation therapy (IGSRT), according to a news release. The guidelines, developed
- Study: Crotoxin Demonstrates Efficacy Against Melanoma with Reduced Toxicityhttps://practicaldermatology.com/news/crotoxin-demonstrates-efficacy-against-melanoma-reduced-toxicity/2467490/A new study in Frontiers in Pharmacology indicated that crotoxin (CTX), a component of snake venom, was associated with antiproliferative effects on melanoma cells. "Melanoma, a highly aggressive skin cancer originating in melanocytes, poses a significant threat due to its metast
- sNDA Submitted for Roflumilast Foam 0.3% for Scalp and Body Psoriasishttps://practicaldermatology.com/news/snda-submitted-roflumilast-foam-03-scalp-and-body-psoriasis/2467457/A supplemental New Drug Application (sNDA) has been submitted for ZORYVE (roflumilast) foam 0.3%, a once-daily, next-generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis, Arcutis Biotherapeutics, Inc., announce
- TRuE-AD3: Ruxolitinib Cream Safe in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/true-ad3-ruxolitinib-cream-safe-pediatric-atopic-dermatitis-patients/2467445/Ruxolitinib applied twice daily did not appear to impact hematologic parameters in any clinically meaningful way, according to a new study. "In two randomized phase 3 studies (TRuE-AD1 and TRuE-AD2) evaluating ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream in adults and adolescent
- Delgocitinib Clinical Trials Data Publishedhttps://practicaldermatology.com/news/delgocitinib-clinical-trials-data-published/2467444/LEO Pharma A/S announced that the findings of the DELTA 1 and DELTA 2 phase 3 clinical trials for delgocitinib cream have been published in the peer-reviewed periodical The Lancet. This is the first time The Lancet has published data on an investigational topical pan-Janus kinase (JAK) inhibitor
- Analysis: Ruxolitinib 1.5% Cream Linked with Repigmentation in Adolescents with Vitiligohttps://practicaldermatology.com/news/phase-3-trials-reveal-enhanced-repigmentation-adolescents-vitiligo/2467443/A new post-hoc analysis indicates significant repigmentation results from the application of 1.5% ruxolitinib cream in patients with nonsegmental vitiligo. The analysis looked at two double-blind, vehicle-controlled studies (the TRuE-V1 and TRuE-V2 phase 3 clinical trials). Patients were
- Study: CBD Cream Shows Promise in Reducing Sun-Induced Skin Injuryhttps://practicaldermatology.com/news/study-cbd-cream-shows-promise-reducing-sun-induced-skin-injury/2467423/New research from the George Washington University School of Medicine and Health Sciences, in collaboration with the Center for Clinical and Cosmetic Research, suggests that cannabidiol (CBD) has potential in preventing skin damage from ultraviolet-A (UVA) radiation. Researchers for the 1